

## RECOMBINANT COLLAGENASES: RATIONALE

### 1. COLLAGEN AND COLLAGENASES




**Collagen** is the main structural protein of mammalian extra-cellular matrix, and it is present in different isoforms (Type I as in dermis, tendons, bone, Type II as in cartilage, Type III as in skin, etc.). Despite the high structural diversity, all collagen molecules share a triple-stranded helical structure, resistant to proteases, that **can only be degraded by specific collagenases**.

**Collagenases** are widely used in regenerative medicine and cell therapy as a result of their ability to disaggregate connective tissues and to facilitate the isolation of cells of interest. Among Collagenases the most important ones are **classes I and II** (isoforms I and II according to the nomenclature of Bond and Van Wart 1984 [1]), expressed by *Clostridium histolyticum*, which are preferred to others, since they are proteolytically **active** practically on **all mammalian collagen isoforms**. Class I and Class II collagenases play different synergic roles, in fact, the class I expresses high collagenolytic activity, specifically hydrolyzing native collagen 3D-helix regions, while the class II expresses a modest activity against 3D collagen helix, acting on linear collagen regions at the motif Pro-Y-Gly-Pro [2-3]. The mix of class I and class II collagenases expresses a **synergic activity** that results in efficient collagen digestion [4].

### 2. 'COLLAGENASE' IS A BLEND

The current technologies to produce collagenases for medical use are based on the culture of *C. histolyticum* and the subsequent protein purification thereof. The resulting 'Collagenase' are actually blends, containing different percentage ratios of the **two collagenase isoforms (class I and class II)**, plus a **number of proteases** (clostripain, trypsin like, caseinase activity, etc.) [5].



## Guidelines

Version 3.0

Revision Date: 15/09/2015




The successful outcome of cell isolation strongly depends on activity, purity, and formulation of 'Collagenase' [4-5]. However, the extraction process of the 'Collagenase' blend from *C. histolyticum* makes it **difficult to obtain reproducible batches**, while the presence of the proteases can contribute to a **lower stability** due to enzymatic autocatalytic processes. Low batches consistency and low stability can lead to low reproducibility and low standardization of protocols for cell isolation [6].

### 3. RECOMBINANT COLLAGENASES: STABILITY AND CONSISTENCY

Abiel has synthesized innovative **Recombinant Collagenases** class I (**COL G**) and class II (**COL H**) by a patented technology in *E. Coli* strain. The recombinant production process (animal-free) ensures a high level of **purity, stability and a remarkable lot-to-lot consistency** [7]. The separation of each enzymatic component avoids instability and allows to formulate **customized and standardized** COL G+ COL H blends for each application [8].

For cell isolation, one generic protease is required to digest the non-collagenous part of the ECM. Mixing COL G + COL H + protease, an efficient ECM digestion is obtained [9].



\* either thermolysin, neutral protease/dispace, pronase. For your specific application please refer to [info@abielbiotech.com](mailto:info@abielbiotech.com)

#### References

- [1] Matsushita O. et al. (1999) *J. Bacteriol.* **181**(3): 923–933.
- [2] Philominathan S.T. et al. (2009) *J. Biol. Chem.* **284**(16) : 10868.
- [3] Matsushita, O. Et al. (1994) *J. Bacteriol.* **176**: 149-156.
- [4] Wolters G.H. et al. (1995) *Diabetes* **44**(2) : 227-233.
- [5] Johnson P.R. et al. (1996) *Cell Transplant* **5**: 437-452.
- [6] Fermo I. et al. (2007) *Transplantation* **84**(12) : 1568-1575.
- [7] Salamone M. et al. (2012) *Chem. Eng. Trans.* **27**: 259-264
- [8] Breite A.G. et al. (2011) *Transplant Proc.* **43**(9) : 3171-3175.
- [9] Salamone M. et al. (2014) *Chem. Eng. Trans.* **38**: 247-252.

For suggestions about your specific protocol or application of COL G and COL H, contact us:

Monica Salamone, PhD-  
R&D Manager  
[m.salamone@abielbiotech.com](mailto:m.salamone@abielbiotech.com)

Giulia Passanisi-  
Product Manager  
[g.passanisi@abielbiotech.com](mailto:g.passanisi@abielbiotech.com)

Tel. +39 091 6615633  
Fax +39 091 661 5628